卒中药物或可治疗阿尔兹海默病

中国一项研究发现，用一种用于治疗急性缺血性卒中的药物依达拉奉治疗一个阿尔兹海默病小鼠模型，能减少β淀粉样肽的沉积，减轻氧化压力，减少神经炎症、神经元流失以及突触机能障碍，并且逆转小鼠的行为缺陷，这提示依达拉奉可能代表了阿尔兹海默病的一种潜在疗法。研究报告4月6日在线发表在美国《国家科学院院刊》上。

Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits

Alzheimer's disease （AD） is one of most devastating diseases affecting elderly people. Amyloid-β （Aβ） accumulation and the downstream pathological events such as oxidative stress play critical roles in pathogenesis of AD. Lessons from failures of current clinical trials suggest that targeting multiple key pathways of the AD pathogenesis is necessary to halt the disease progression. Here we show that Edaravone, a free radical scavenger that is marketed for acute ischemic stroke, has a potent capacity of inhibiting Aβ aggregation and attenuating Aβ-induced oxidation in vitro. When given before or after the onset of Aβ deposition via i.p. injection, Edaravone substantially reduces Aβ deposition, alleviates oxidative stress, attenuates the downstream pathologies including Tau hyperphosphorylation, glial activation, neuroinflammation, neuronal loss, synaptic dysfunction, and rescues the behavioral deficits of APPswe/PS1 mice. Oral administration of Edaravone also ameliorates the AD-like pathologies and memory deficits of the mice. These findings suggest that Edaravone holds a promise as a therapeutic agent for AD by targeting multiple key pathways of the disease pathogenesis.